Artiria Medical, a Swiss neurovascular MedTech company developing next-generation neuro interventional products for stroke and aneurysms, closed a USD 6m series A2 financing round. The round was led by 4FOX Ventures, with the Wyss Center
Tags :Vincent S. Reardon
Memo Therapeutics, a late-stage biotech company developing best-in-class therapeutic antibodies closed a CHF 25 million series C financing round led by Pureos Bioventures. Existing investors Swisscanto, Vesalius Biocapital, Adjuvant Capital, Verve Ventures, Schroders Capital, GF Group,
Epiterna, a Swiss longevity company founded in 2022 by Alejandro Ocampo and Kevin Perez as a spin-off from Alejandro Ocampo’s laboratory at the University of Lausanne, has raised EUR 10 million from Prima Materia, an investment
